MEDCHEM AT QUB/GSK · New methodologies to synthetise unnatural nucleosides, known and putative antiproliferative agents
6РП — Действия „Мария Кюри“
- Период
- 2006-09-01 → 2010-08-31
- Финансиране от ЕС
- 874 196 €
- Участници
- 1
- Схема
- IIF
Линиите свързват координатора с партньорите.
Накратко на български
Нови методи за синтезиране на изкуствени нуклеозиди и гликозиди, като например аналоги на захари и фосфорни съединения, са в центъра на работата. Те служат за създаване на нови антивирусни и антибактериални средства.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Final Activity Report Summary - MEDCHEM AT QUB/GSK (New methodologies to synthetise unnatural nucleosides, known and putative antiproliferative agents)
MEDCHEM at QUB/GSK aimed at providing a structure for scientists in the early stage of their career wanting to acquire high quality experience and training in the pharmaceutical industry while pursuing an innovative and academically challenging PhD programme. The research training carried out at Queen's University Belfast (QUB) and at GlaxoSmithKline (GSK) offered an opportunity to most early stage researchers (ESRs) enrolled on this program, who were 10 in total over the four project years, to acquire a fully integrated academic and industrial training specialised in research areas of medicinal, biological and synthetic chemistry. All researchers enrolled on this programme had first-hand access to industrial perspective to their project as well as on site experience. While each researcher pursued individual research, the overall perspective of the programme was to establish novel methodologies to access c-glycosides and c-nucleosides as putative antiviral or antibacterial agents. In order to address this we developed complementary synthetic methods to prepare novel and structurally diverse c-nucleoside and c-glycoside scaffolds. The explored chemical strategies involved chemoenzymatic processes, multi-step one pot syntheses and use of renewable resources, in addition to the development of novel advanced synthetic methodologies and extensive analytical protocols. In addition to carrying out traditional carbon based chemistry, phosphorus based chemistry was extensively pursued, particularly in relation to the preparation of sugar and nucleoside diphosphate analogues such as nicotinamide adenine dinucleotide, adenosine diphosphate ribose and mannose diphosphate guanosine.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
Dr Migaud and colleagues, all academic medicinal synthetic chemists at Queen's University Belfast (Northern Ireland, academic partner), in collaboration with GlaxoSmithKline (Stevenage, UK, Industrial partner via Dr McDonald) seek financial support to host an Early Stage Research Training programme for four post-graduate researchers (36 months each) who would pursue a PhD training programme in Organic and Medicinal Chemistry at QUB/GSK and for the equivalent of four visiting EST fellows (12 months each) enrolled in a PhD programme in another EU or affiliated state university.The principal objective of the proposed activities is to develop a unique environment for innovative training of chemists in order to facilitate their integration to the ever-evolving world of interdisciplinary research at the Pharmaceutics and Life Science interface.To achieve excellence in interdisciplinary research of this type, hands-on and taught training activities will maximise acquisition of expertise in the fields of organic synthesis, medicinal chemistry, enzymology, biology and biotechnology, to help the fellows attain fundamental understanding in:- Design of inhibitors and/or ligands based on structural knowledge - Development of organic synthetic methodologies- Analysis of biological results and iterative design of new compounds- Prediction of biological activities based on structural data- Design of antiproliferative agents based on pharmacodynamics, pharmacokinetics and toxicological results.The collaboration between QUB and GSK achieved through this programme will also maximise the transfer of research competencies between the academically-based medicinal chemistry research laboratories where synthetic methodologies are devised and the pharmaceutical industry where high through-put approach is the driving force, thus exploiting European research excellence by promoting integrated research projects.
Оригинален текст от CORDIS (на английски).
Участници
- QUEEN'S UNIVERSITY BELFAST · BELFASTКоординаторОбединеното кралство
Връзки
Данни: CORDIS, © Европейски съюз